The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses long-term outcomes of epcoritamab monotherapy in Richter’s transformation from the Epcore CLL-1 trial (NCT04623541). Prof. Kater highlights that patients treated with epcoritamab as first-line therapy showed sustained remission and a median overall survival of 27 months, whereas those who received the therapy after chemoimmunotherapy had a less favorable response. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
